These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 15151519)

  • 1. Revisiting the Effect of Pharmaceuticals on Transmission Stage Formation in the Malaria Parasite
    Thommen BT; Passecker A; Buser T; Hitz E; Voss TS; Brancucci NMB
    Front Cell Infect Microbiol; 2022; 12():802341. PubMed ID: 35223540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study.
    Reiter-Owona I; Hlobil H; Enders M; Klarmann-Schulz U; Gruetzmacher B; Rilling V; Hoerauf A; Garweg JG
    Eur J Med Res; 2020 Nov; 25(1):59. PubMed ID: 33228795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.
    Ben-Harari RR; Goodwin E; Casoy J
    Drugs R D; 2017 Dec; 17(4):523-544. PubMed ID: 28879584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.
    Mahmood I; Tegenge MA
    Clin Pharmacokinet; 2017 Dec; 56(12):1567-1576. PubMed ID: 28405936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy.
    Salman S; Griffin S; Kose K; Pitus N; Winmai J; Moore B; Siba P; Ilett KF; Mueller I; Davis TM
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1693-700. PubMed ID: 21282434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance.
    Hodel EM; Kabanywanyi AM; Malila A; Zanolari B; Mercier T; Beck HP; Buclin T; Olliaro P; Decosterd LA; Genton B
    PLoS One; 2009 Dec; 4(12):e8184. PubMed ID: 20011529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women.
    Karunajeewa HA; Salman S; Mueller I; Baiwog F; Gomorrai S; Law I; Page-Sharp M; Rogerson S; Siba P; Ilett KF; Davis TM
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4368-76. PubMed ID: 19620325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of chloroquine and sulfadoxine and treatment response in children with malaria: suggestions for an improved dose regimen.
    Obua C; Hellgren U; Ntale M; Gustafsson LL; Ogwal-Okeng JW; Gordi T; Jerling M
    Br J Clin Pharmacol; 2008 Apr; 65(4):493-501. PubMed ID: 18294337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
    Meneceur P; Bouldouyre MA; Aubert D; Villena I; Menotti J; Sauvage V; Garin JF; Derouin F
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1269-77. PubMed ID: 18212105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.
    Schmidt DR; Hogh B; Andersen O; Hansen SH; Dalhoff K; Petersen E
    Eur J Pediatr; 2006 Jan; 165(1):19-25. PubMed ID: 16133245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications.
    Barnes KI; Little F; Smith PJ; Evans A; Watkins WM; White NJ
    Clin Pharmacol Ther; 2006 Dec; 80(6):582-96. PubMed ID: 17178260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of ocular toxoplasmosis. Part 1: Basic principles and diagnosis].
    Mittelviefhaus H
    Kinderarztl Prax; 1993 May; 61(3):90-6. PubMed ID: 8326704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of toxoplasmosis].
    Matérnova V; Shevkunova EA
    Klin Med (Mosk); 1979 May; 57(5):21-7. PubMed ID: 384081
    [No Abstract]   [Full Text] [Related]  

  • 14. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.
    Trenque T; Simon N; Villena I; Chemla C; Quereux C; Leroux B; Jaussaud R; Rémy G; Dupouy D; Millart H; Pinon JM; Urien S
    Br J Clin Pharmacol; 2004 Jun; 57(6):735-41. PubMed ID: 15151519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.
    Corvaisier S; Charpiat B; Mounier C; Wallon M; Leboucher G; Al Kurdi M; Chaulet JF; Peyron F
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3794-800. PubMed ID: 15388436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic disposition of sulfadoxine in children with acute uncomplicated falciparum malaria treated with sulfadoxine-pyrimethamine in South West Nigeria.
    Gbotosho GO; Happi CT; Sijuade A; Sowunmi A; Oduola A
    Am J Ther; 2012 Sep; 19(5):338-45. PubMed ID: 19918170
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.